Tesamorelin/ CJC-1295 No DAC/ Ipamorelin – GH Stack

This research blend combines three growth hormone–axis peptides in a single lyophilized vial: tesamorelin, CJC-1295 without DAC (Mod GRF 1-29), and ipamorelin. The formulation pairs two structurally distinct GHRH analogs with a selective growth hormone secretagogue receptor (GHS-R) agonist, allowing concurrent investigation of GHRH and ghrelin / GHS pathway activation. Tesamorelin is a stabilized 44-amino-acid GHRH analog with a trans-3-hexenoic acid modification at the N-terminus and an extended plasma half-life. CJC-1295 (no DAC) is a 29-amino-acid modified GRF(1-29) sequence with substitutions designed to resist DPP-IV cleavage, offering a shorter pulsatile profile. Ipamorelin is a selective pentapeptide GHS-R agonist studied for its specificity over cortisol, prolactin, ACTH, and aldosterone pathways.

Benefits (Research Focus)

• Combined GHRH + GHS-R activation — studied for paired pathway stimulation of the somatotropic axis

• Pulsatile GH release — investigated for physiologic-pattern growth hormone release in research models

• IGF-1 signaling — explored for downstream hepatic IGF-1 production and somatotropic endpoints

• Visceral adipose research — examined for differential effects on visceral adipose tissue in lipodystrophy models

• Hormone selectivity — researched for ipamorelin’s reported minimal off-target effects on cortisol, prolactin, and ACTH

What Researchers Look At

• Plasma GH and IGF-1 dynamics following paired peptide administration

• Pulsatile vs sustained GH release across paired GHRH and GHS-R stimulation

• Visceral adipose tissue and lipid metabolism endpoints in lipodystrophy models

• Cortisol, prolactin, and ACTH response panels (selectivity markers)

• DPP-IV resistance and peptide pharmacokinetic profiles across components

Quick Specs

• Form: Lyophilized white powder

• Tesamorelin: 6.7 mg per vial

• CJC-1295 (no DAC): 3.7 mg per vial

• Ipamorelin: 3.7 mg per vial

• Total Peptide Content: 14 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC (per component)

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound 1: Tesamorelin

• Class: Stabilized GHRH(1-44) analog with N-terminal trans-3-hexenoic acid modification

• Formula / M.W.: C₂₂₁H₃₆₆N₇₂O₆₇S, ~5135.86 g/mol

• CAS: 218949-48-5

• Compound 2: CJC-1295 without DAC (Mod GRF 1-29)

• Class: Modified GHRH(1-29) analog with D-Ala², Gln⁸, Ala¹⁵, Leu²⁷ substitutions

• Formula / M.W.: C₁₅₂H₂₅₂N₄₄O₄₂, ~3367.95 g/mol

• CAS: 863288-34-0

• Compound 3: Ipamorelin

• Class: Selective ghrelin / GHS-R1a agonist (pentapeptide)

• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

• Formula / M.W.: C₃₈H₄₉N₉O₅, ~711.85 g/mol

• CAS: 170851-70-4

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• Tesamorelin / CJC-1295 No DAC / Ipamorelin Blend VPeptide — May 4, 2026

• Tesamorelin / CJC-1295 No DAC / Ipamorelin Blend VPeptide — July 30, 2026 – Batch# T/I/C07-1112